Recent studies have reported that LGK974 and RSPO3 antibodies may be beneficial at in vitro and in vivo levels, however, the development of targeted therapeutics for colorectal cancer patients with P:R fusions is still in its infancy [18, 19]. This evidence concerns the gene RSPO3 and colorectal cancer.